Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
POINT Biopharma Global Inc. (PNT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 SC 14D9 Form SC 14D9 - Solicitation, recommendation statements:
10/13/2023 SC TO-T Form SC TO-T - Tender offer statement by Third Party:
10/03/2023 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
10/03/2023 SC TO-C Form SC TO-C - Written communication relating to an issuer or third party:
10/03/2023 SC 13D/A SILBER ALLAN C reports a 8.8% stake in POINT Biopharma Global Inc.
10/03/2023 SC14D9C Form SC14D9C - Written communication relating to third party tender offer:
10/03/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "AGREEMENT AND PLAN OF MERGER dated as of OCTOBER 2, 2023, among ELI LILLY AND COMPANY, YOSEMITE FALLS ACQUISITION CORPORATION and POINT BIOPHARMA GLOBAL INC.",
"TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT , dated as of October 2, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation , Yosemite Falls Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent , and the stockholders of POINT Biopharma Global Inc., a Delaware corporation , set forth on Schedule A hereto .  All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement . WHEREAS, as of the date hereof, each Stockholder is the record or beneficial owner of the number of shares of Company Common Stock, Company PSUs and Company Stock Options set forth opposite such Stockholder’ s name on Schedule A ; WHEREAS...",
"TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT , dated as of October 2, 2023, is entered into by and among Eli Lilly and Company, an Indiana corporation , Yosemite Falls Acquisition Corporation, a Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent , and the stockholders of POINT Biopharma Global Inc., a Delaware corporation , set forth on Schedule A hereto .  All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement . WHEREAS, as of the date hereof, each Stockholder is the record or beneficial owner of the number of shares of Company Common Stock, Company PSUs and Company Stock Options set forth opposite such Stockholder’ s name on Schedule A ; WHEREAS...",
"Schedule A",
"Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies"
08/14/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights Enrollment in PNT2002's SPLASH trial is complete and top line data is expected in the fourth quarter of 2023"
08/03/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/27/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A BIOTECHNOLOGY VALUE FUND L P reports a 8.7% stake in POINT Biopharma Global Inc.
02/07/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
02/03/2023 SC 13G BlackRock Inc. reports a 5.1% stake in POINT Biopharma Global Inc.
11/22/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/26/2022 SC 13D/A RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in POINT BIOPHARMA GLOBAL INC.
09/26/2022 SC 13G BIOTECHNOLOGY VALUE FUND L P reports a 5.4% stake in POINT Biopharma Global Inc.
09/16/2022 SC 13D/A RA CAPITAL MANAGEMENT, L.P. reports a 8.6% stake in POINT BIOPHARMA GLOBAL INC.
09/14/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "13,900,000 Shares1 POINT Biopharma Global Inc.",
"POINT Biopharma Global Inc. 4850 West 78th Street",
"POINT Biopharma Prices Public Offering of Common Stock"
09/14/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/13/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/13/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "POINT Biopharma Announces Proposed Public Offering of Common Stock"
09/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022",
"PNT2002 1 3.7 0 0.0"
09/06/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial"
08/29/2022 SC 13D/A RA CAPITAL MANAGEMENT, L.P. reports a 9.9% stake in POINT BIOPHARMA GLOBAL INC.
08/12/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/12/2022 EFFECT Form EFFECT - Notice of Effectiveness:
07/11/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy